Sex and cannabinoid CB1 genotype differentiate palatable food and cocaine self-administration behaviors in mice

Behavioural Pharmacology

Volumn 20, Issue 7, 2009, Pages 605-613

  Ward, Sara Jane ^a   Walker, Ellen A ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

CB1 receptor; Knockout; Mouse; Palatable food; Self administration; Sex differences; SR141716

Indexed keywords

CANNABINOID 1 RECEPTOR; COCAINE; ENSURE; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; FEMALE; FOOD PREFERENCE; GENE INTERACTION; GENOTYPE; MALE; MOUSE; NONHUMAN; PALATABILITY; REINFORCEMENT; REWARD; SEX DIFFERENCE; WILD TYPE;

ANIMALS; COCAINE; CONDITIONING, OPERANT; CORN OIL; FEEDING BEHAVIOR; FEMALE; GENOTYPE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; REINFORCEMENT SCHEDULE; SELF ADMINISTRATION; SEX CHARACTERISTICS;

EID: 70349664760     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328331ba30     Document Type: Article

References (42)

1. Abel EL (1975). Cannabis: Effects on hunger and thirst. Behav Biol 15:255-281.
2. Anthenelli RM, Despres JP (2004). Effects of Rimonabant in the reduction of major cardiovascular risk factors. New Orleans, LA: Results from the STRATUS-US trial (smoking cessation in smokers motivated to quit), in American College of Cardiology 53rd Annual Scientific Session; 7-10.
3. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, Le Fur G (1997). Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 132:104-106.
4. Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155-163.
5. Caine SB, Negus SS, Mello NK (1999). Method for training operant responding and evaluating cocaine self-administration behavior in mutant mice. Psychopharmacology 147:22-24.
6. Carroll ME, Morgan AD, Lynch WJ, Campbell UC, Dess NK (2002). Intravenous cocaine and heroin self-administration in rats selectively bred for differential saccharin intake: Phenotype and sex differences. Psychopharmacology (Berl) 161:304-313.
7. Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M, Fratta W (2001). Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 118:61-65.
8. Craft RM (2005). Sex differences in behavioral effects of cannabinoids. Life Sci 77:2471-2478.
9. Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, Zimmer A, Martin BR (2000). Levels, metabolism, and pharmacological activity of anandamide in CB (1) cannabinoid receptor knockout mice: Evidence for non-CB (1), non-CB (2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 75:2434-2444.
10. Diaz S, Farhang B, Hoien J, Stahlman M, Adatia N, Cox JM, Wagner EJ (2009). Sex differences in the cannabinoid modulation of appetite, body temperature and neurotransmission at POMC synapses. Neuroendocrinology 89:424-440. [Epub ahead of print]
11. Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, et al. (2003). Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: Evidence for a 'CB3' receptor. Eur J Pharmacol 461:27-34.
12. Foltin RW, Haney M (2007). Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates. Pharmacol Biochem Behav 86:766-773.
13. Foltin RW, Fischman MW, Byrne MF (1988). Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 11:1-14.
14. Gerald TM, Howlett AC,Ward GR, Ho C, Franklin SO (2008). Gene expression of opioid and dopamine systems in mouse striatum: Effects of CB1 receptors, age and sex. Psychopharmacology 198:497-508.
15. Griffin WC III, Randall PK, Middaugh LD (2007). Intravenous cocaine selfadministration: Individual differences in male and female C57BL/6J mice. Pharmacol Biochem Behav 87:267-279.
16. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002). The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16:1395-1398.
17. Higgs S, Williams CM, Kirkham TC (2003). Cannabinoid influences on palatability: Microstructural analysis of sucrose drinking after delta(9)- tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology 165:370-377.
18. Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, et al. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 96: 14136-14141.
19. Le Foll B, Goldberg SR (2005). Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther. 312:875-883.
20. Lynch WJ (2008). Acquisition and maintenance of cocaine self-administration in adolescent rats: Effects of sex and gonadal hormones. Psychopharmacology (Berl) 197:237-246.
21. McLaughlin PJ, Winston K, Swezey L, Wisniecki A, Aberman J, Tardif DJ, et al. (2003). The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 14:583-588.
22. Miller CC, Murray TF, Freeman KG, Edwards GL (2004). Cannabinoid agonist, CP 55 940, facilitates intake of palatable foods when injected into the hindbrain. Physiol Behav 80:611-616.
23. National Research Council of the National Academies (2003). Guidelines for the care and use of mammals in neuroscience and behavioral research. Washington DC: The National Academies Press.
24. Parolaro D, Viganò D, Rubino T (2005). Endocannabinoids and drug dependence. Curr Drug Targets CNS Neurol Disord 4:643-655.
25. Penetar DM, Kouri EM, Gross MM, McCarthy EM, Rhee CK, Peters EN, Lukas SE (2005). Transdermal nicotine alters some of marihuana's effects in male and female volunteers. Drug Alcohol Depend 79:211-223.
26. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 295:761-775.
27. Poncelet M, Maruani J, Calassi R, Soubrie P (2003). Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett 343:216-218.
28. Richardson NR, Roberts DC (1996). Progressive ratio schedules in drug self-administration studies in rats: A method to evaluate reinforcing efficacy. J Neurosci Methods 66:1-11.
29. Roberts DC, Bennett SA, Vickers GJ (1989). The estrous cycle affects cocaine self-administration on a progressive ratio schedule in rats. Psychopharmacology (Berl) 98:408-411.
30. Roth ME, Cosgrove KP, Carroll ME (2004). Sex differences in the vulnerability to drug abuse: A review of preclinical studies. Neurosci Biobehav Rev 28:533-546.
31. Sanchis-Segura C, Cline BH, Marsicano G, Lutz B, Spanagel R (2004). Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology (Berl) 176:223-232.
32. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR (2003). The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)- 4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 306:93-102.
33. Soria G, Mendizabal V, Tourino C, Robledo P, Ledent C, Parmentier M, et al. (2005). Lack of CB1 Cannabinoid Receptor Impairs Cocaine Self- Administration. Neuropsychopharmacology 30:1670-1680.
34. Thornton-Jones ZD, Vickers SP, Clifton PG (2005). The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food. Psychopharmacology (Berl) 179:452-460.
35. Traynor K (2007). Panel advises against rimonabant approval. Am J Health Syst Pharm 64:1460-1461.
36. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S; RIO-Europe Study Group (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397. (Pubitemid 40523733)
37. Vemuri VK, Janero DR, Makriyannis A (2008). Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome. Physiol Behav 93:671-686.
38. Ward SJ, Dykstra LA (2005). The role of CB1 receptors in sweet versus fat reinforcement: Effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol 16:381-388.
39. Ward SJ, Walker EA, Dykstra LA (2007). Effect of cannabinoid CB1 receptor antagonist SR141716A and CB1 receptor knockout on cue-induced reinstatement of Ensure and corn-oil seeking in mice. Neuropsychopharmacology 32:2592-2600.
40. Ward SJ, Lefever TW, Jackson C, Tallarida RJ, Walker EA (2008). Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: A dose-addition analysis study in mice. J Pharmacol Exp Ther 325:567-576.
41. Zimmer A (1992). Manipulating the genome by homologous recombination in embryonic stem cells. Annu Rev Neurosci 15:115-137.
42. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 96:5780-5785. (Pubitemid 29234695)